ALKEM2024-01-012024-03-31 ALKEM2024-01-012024-03-31 ALKEM2024-01-012024-03-31in-bse-fin:OneOperatingExpenses01Member ALKEM2024-01-012024-03-31in-bse-fin:FourOperatingExpenses01Member ALKEM2024-03-31 ALKEM2024-01-012024-03-31in-bse-fin:OneItemsThatWillNotBeReclassifiedToProfitAndLoss01Member ALKEM2024-01-012024-03-31in-bse-fin:FourItemsThatWillNotBeReclassifiedToProfitAndLoss01Member ALKEM2024-01-012024-03-31in-bse-fin:OneItemsThatWillBeReclassifiedToProfitAndLoss01Member ALKEM2024-01-012024-03-31in-bse-fin:FourItemsThatWillBeReclassifiedToProfitAndLoss01Member iso4217:INRxbrli:purexbrli:sharesiso4217:INRxbrli:shares 539523 ALKEM NOTLISTED Alkem Laboratories Limited Equity 2023-04-01 2024-03-31 2024-05-29 2024-05-16 INR Millions Yearly 11:30:00 14:00:00 2024-05-29 2024-05-29 true Cash Flow Indirect Declaration of unmodified opinion Single segment The Company is exclusively engaged in pharmaceutical business 2024-01-01 2024-03-31 Audited Consolidated 29358200000.00 881700000.00 30239900000.00 7987600000.00 3807000000.00 -720600000.00 5058300000.00 268600000.00 834300000.00 9206100000.00 26441300000.00 3798600000.00 -125200000.00 3673400000.00 838500000.00 -209900000.00 628600000.00 0.00 3044800000.00 0.00 0.00 0.00 0.00 3044800000.00 -76500000.00 2968300000.00 2935600000.00 109200000.00 -76800000.00 300000.00 239100000.00 2 24.55 24.55 0.00 0.00 24.55 24.55 1. The Consolidated Financial results are prepared in accordance with Ind AS 110 'Consolidated Financial Statements'. 2.The above audited consolidated financial results of Alkem Laboratories Limited and its subsidiaries (collectively called the “Group”) were reviewed and recommended by the Audit Committee on 28 May 2024 and subsequently approved by the BOD at its meeting held on 29 May 2024. The auditors have expressed an unmodified opinion on the financial results for the year ended 31 March 2024. The figures for the quarter ended 31 March 2024 and 31 March 2023 are balancing figures between audited figures in respect of full financial year and the unaudited published year-to-date figures up to 31 Dec 2023 and 31 Dec 2022 respectively, which were subjected to limited review. 3.a. Consequent to changes in market dynamics and assessment of recoverable value where indicators of impairment were identified, the group has recognized an impairment loss of: - Rs 415.6 Million in respect of its plant located at Indore during the quarter ended 31 March 2024 - Rs 576.6 Million in respect to the plant located at St. Louis, USA, a unit under S&B Pharma LLC, a subsidiary of the Company in the quarter ended 30 September 2023 and Rs 1,029.8 Million in the quarter and year ended 31 March 2023. The plant was subsequently sold at Rs 656.0 Million during the quarter ended 31 December 2023. These amounts are reflected under 'Exceptional Items' in the respective quarters and years. Deferred tax assets amounting to Rs 1,197.2 Million relating to the assets and business associated with the plant at St. Louis were also derecognised in the consolidated financial results for the quarter ended 31 March 2023 since utilization of these assets could no longer be determined. 3.b. In the quarter ended 31 Dec 2023, a Cyber security incident which compromised business email IDs of certain employees at one of the Group’s subsidiaries, resulted in a fraudulent transfer of Rs 513.1 Million. This was shown as an expense under 'Exceptional Items' for the quarter ended 31 Dec 2023. During the current quarter, the Group has recovered an amount of Rs 290.4 Million which is shown as income under 'Exceptional Items' resulting in a net amount of Rs 222.7 Million shown as 'Exceptional items' in the Statement of Profit and Loss for the year ended 31 March 2024. 4. The BOD in its meeting held on 29 May 2024 has recommended a final dividend of Rs 5 (Rupees Five only) per equity share (face value of Rs 2 each) in addition to the interim dividend of Rs 35 (Rupees Thirty five only) per equity share (face value of Rs 2 each) declared on 9 Feb 2024. The final dividend is subject to approval at the ensuing AGM of the Company. Single segment 2023-04-01 2024-03-31 Audited Consolidated 126675800000.00 3108400000.00 129784200000.00 32945900000.00 16288700000.00 141200000.00 22010100000.00 1124100000.00 2993000000.00 32835000000.00 108338000000.00 21446200000.00 -1214900000.00 20231300000.00 4222800000.00 -2106100000.00 2116700000.00 0.00 18114600000.00 0.00 0.00 0.00 0.00 18114600000.00 200400000.00 18315000000.00 17957700000.00 156900000.00 206500000.00 -6100000.00 239100000.00 2 102881516000.00 150.19 150.19 0.00 0.00 150.19 150.19 Other Expenses 9206100000.00 Other Expenses 32835000000.00 4023400000.00 21614600000.00 1484000000.00 0.00 4167400000.00 2945800000.00 101700000.00 0.00 0.00 3348000000.00 0.00 0.00 1202200000.00 4550200000.00 15148300000.00 1621200000.00 51633200000.00 26611800000.00 1489900000.00 22528100000.00 4550700000.00 11242800000.00 90700000.00 29302000000.00 69204200000.00 0.00 8299800000.00 104115800000.00 0.00 0.00 155749000000.00 239100000.00 102881500000.00 103120600000.00 107144000000.00 400000000.00 0.00 5002500000.00 5402500000.00 2998600000.00 258400000.00 8659500000.00 11739700000.00 17481200000.00 6609500000.00 35830400000.00 2296500000.00 1268700000.00 549900000.00 0.00 39945500000.00 0.00 0.00 48605000000.00 155749000000.00 ... continued 5. In Sep 2023, the Income Tax Department ( the Department ) conducted a survey under Section 133A of the Income Tax Act,1961 ('the Survey') on the Company and a few of its domestic subsidiaries ('respective companies'). During the Survey proceedings and subsequently, the respective companies have provided necessary information and responses to the Department in addition to the documents, data backups, and other information provided during the Survey. Pursuant to the Survey, the department has initiated re-assessment proceedings u/s 148 of the Income-tax Act, 1961 (“the IT Act”) in April, 2024 challenging the respective companies’ eligibility to claim deduction majorly under Section 80IE of the IT Act for its manufacturing facilities situated in Sikkim and allowability of certain expenses under Section 37(1) of the IT for assessment years 2017-18 to 2022-23. The respective companies have duly responded to the notices and rebutted the contentions of the Department. No demands have been raised as of date. The respective companies have evaluated the aforesaid matters raised by the Department and believe that based on documentary evidence available, interpretation of Income-tax laws and opinion from independent Tax Counsel, the respective companies have strong grounds to succeed in the above matters. Where a liability has been considered probable, adequate tax provisions have been accrued. Accordingly, no other material adjustments have been considered necessary to these consolidated financial results. 6. The Group operates in one reportable business segment i.e. Pharmaceuticals , accordingly no separate disclosure of segment has been made. 1124095000.00 -734042000.00 -2219877000.00 0.00 0.00 -1351129000.00 0.00 0.00 0.00 5252802000.00 0.00 0.00 0.00 2993035000.00 0.00 -1464684000.00 0.00 0.00 0.00 588926000.00 1922000.00 2757734000.00 0.00 0.00 0.00 0.00 1889436000.00 0.00 0.00 3318906000.00 23550206000.00 0.00 0.00 0.00 4069364000.00 0.00 19480842000.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 724770000.00 2592940000.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 26180871000.00 36792504000.00 0.00 0.00 0.00 0.00 1922000.00 2392771000.00 0.00 0.00 0.00 -10085110000.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 400008000.00 5208913000.00 323239000.00 0.00 5404900000.00 913067000.00 0.00 0.00 -11450111000.00 -2054379000.00 -20547000.00 -2074926000.00 2737980000.00 663054000.00 Remeasurements of defined benefit plans 2300000.00 Remeasurements of defined benefit plans -93400000.00 2300000.00 -93400000.00 2100000.00 -29800000.00 Foreign currency translation difference of foreign operations -76700000.00 Foreign currency translation difference of foreign operations 264000000.00 -76700000.00 264000000.00 0.00 0.00